bluebird Tender Offer Extended by Carlyle and SK Capital
Deal News | Apr 16, 2025 | The Carlyle Group
Carlyle and SK Capital Partners have extended their tender offer for acquiring bluebird bio, a gene therapy company, until May 2, 2025. This extension is to allow more time to satisfy remaining conditions, notably regulatory approvals. The tender offer initially scheduled to expire on April 18, 2025, involves the acquisition of all outstanding common stock of bluebird bio. As of April 15, 2025, Equiniti Trust Company reported approximately 700,288 shares of bluebird stock have been tendered and not withdrawn. The offer is subject to customary conditions, including a majority tender of outstanding shares and regulatory approval. bluebird bio, known for pioneering gene therapy for severe genetic diseases, continues to operate as a standalone commercial entity. Carlyle, a global investment firm, and SK Capital, focused on life sciences and specialty materials, jointly spearhead the acquisition effort. Public filings for the tender offer can be accessed at the SEC website.
Sectors
- Biotechnology
- Private Equity
- Healthcare
Geography
- United States – The companies involved, Carlyle Group, SK Capital, and bluebird bio, are headquartered in the United States, and the tender offer is regulated by U.S. financial authorities.
Industry
- Biotechnology – bluebird bio operates in the biotechnology sector specializing in gene therapy for severe genetic diseases.
- Private Equity – Carlyle Group and SK Capital are private equity firms involved in the acquisition of bluebird bio.
- Healthcare – The acquisition involves investment in healthcare innovation, with bluebird bio focusing on pioneering gene therapy solutions.
Financials
- Approximately 700,288 shares – Number of shares of bluebird bio common stock tendered as of April 15, 2025.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| bluebird bio, Inc. | Target company | Company | A gene therapy company focused on severe genetic diseases. |
| Carlyle Group | Private Equity firm, acquirer | Company | A global investment firm with a focus on multiple business segments, including Global Private Equity. |
| SK Capital Partners | Private Equity firm, acquirer | Company | An investment firm with a focus on transformation in the life sciences, specialty materials, and ingredients sectors. |
| Beacon Parent Holdings, L.P. | Parent company | Company | Involved in the acquisition of bluebird bio through its subsidiary, Merger Sub. |
| Beacon Merger Sub, Inc. | Bidder (subsidiary of Parent company) | Company | An acquisition vehicle for the tender offer of bluebird bio. |
| Equiniti Trust Company, LLC | Depositary | Company | Responsible for managing the shares tendered in the offer. |